• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为乙酰胆碱酯酶和丁酰胆碱酯酶抑制剂的亚磺酰化5-氨基吡唑的设计与开发:探索其对阿尔茨海默病中β-淀粉样蛋白聚集抑制的意义

Design and development of sulfenylated 5-aminopyrazoles as inhibitors of acetylcholinesterase and butyrylcholinesterase: exploring the implication for Aβ aggregation inhibition in Alzheimer's disease.

作者信息

Rani Payal, Chahal Sandhya, Ranolia Anju, Kumar Devendra, Kataria Ramesh, Kumar Parvin, Singh Devender, Duhan Anil, Jha Vibhu, Wahajuddin Muhammad, Joshi Gaurav, Sindhu Jayant

机构信息

Department of Chemistry, COBS&H, CCS Haryana Agricultural University Hisar 125004 India

Department of Chemistry, Chaudhary Ranbir Singh University Jind 126102 India.

出版信息

RSC Med Chem. 2025 Apr 17. doi: 10.1039/d5md00069f.

DOI:10.1039/d5md00069f
PMID:40256309
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12005478/
Abstract

Current therapeutic regimens approved to treat Alzheimer's disease (AD) provide symptomatic relief by replenishing the acetylcholine levels in the brain by inhibiting AChE. However, these drugs don't halt or slow down the progression of Alzheimer's disease, which remains a major challenge. Evidence suggests a significant increase in BuChE activity with a decrease in AChE activity as the AD progresses along with the Aβ aggregation. To address this unmet need, we rationally developed sulfenylated 5-aminopyrazoles (3a-3o) electro-organic synthesis in good to excellent yields (68-89%) and duly characterized them using spectrophotometric techniques. The compounds were tested for acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibition, with 3b (4-NO) showing the highest potency. It exhibited IC values of 1.634 ± 0.066 μM against AChE and 0.0285 ± 0.019 μM against BuChE, outperforming donepezil and tacrine. Admittedly, 3b effectively inhibited Aβ aggregation and enhanced working memory, as indicated by the Y-maze test, besides portraying no cytotoxicity. The outcome was further corroborated using techniques, leading to the elucidation of plausible inhibition and metabolism mechanisms.

摘要

目前批准用于治疗阿尔茨海默病(AD)的治疗方案,通过抑制乙酰胆碱酯酶(AChE)来补充大脑中的乙酰胆碱水平,从而缓解症状。然而,这些药物并不能阻止或减缓阿尔茨海默病的进展,这仍然是一个重大挑战。有证据表明,随着AD的进展以及淀粉样β蛋白(Aβ)的聚集,丁酰胆碱酯酶(BuChE)活性显著增加,而AChE活性降低。为了满足这一未被满足的需求,我们合理地开发了亚磺酰化5-氨基吡唑(3a - 3o),通过有机电合成以良好至优异的产率(68 - 89%)得到,并使用分光光度技术对其进行了充分表征。对这些化合物进行了乙酰胆碱酯酶(AChE)和丁酰胆碱酯酶(BuChE)抑制测试,其中3b(4 - NO)显示出最高的效力。它对AChE的IC值为1.634 ± 0.066 μM,对BuChE的IC值为0.0285 ± 0.019 μM,优于多奈哌齐和他克林。诚然,3b除了没有细胞毒性外,还能有效抑制Aβ聚集,并通过Y迷宫试验表明能增强工作记忆。使用相关技术进一步证实了这一结果,从而阐明了可能的抑制和代谢机制。

相似文献

1
Design and development of sulfenylated 5-aminopyrazoles as inhibitors of acetylcholinesterase and butyrylcholinesterase: exploring the implication for Aβ aggregation inhibition in Alzheimer's disease.作为乙酰胆碱酯酶和丁酰胆碱酯酶抑制剂的亚磺酰化5-氨基吡唑的设计与开发:探索其对阿尔茨海默病中β-淀粉样蛋白聚集抑制的意义
RSC Med Chem. 2025 Apr 17. doi: 10.1039/d5md00069f.
2
6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease.6-甲基尿嘧啶衍生物作为用于治疗阿尔茨海默病的乙酰胆碱酯酶抑制剂
Int J Risk Saf Med. 2015;27 Suppl 1:S69-71. doi: 10.3233/JRS-150694.
3
Design, synthesis, and biological evaluation of novel donepezil-tacrine hybrids as multi-functional agents with low neurotoxicity against Alzheimer's disease.新型多奈哌齐-他克林杂合体的设计、合成与生物评价:具有低神经毒性的阿尔茨海默病多功能治疗药物。
Bioorg Chem. 2024 Feb;143:107010. doi: 10.1016/j.bioorg.2023.107010. Epub 2023 Nov 29.
4
Discovery of new phenyl sulfonyl-pyrimidine carboxylate derivatives as the potential multi-target drugs with effective anti-Alzheimer's action: Design, synthesis, crystal structure and in-vitro biological evaluation.发现新的苯磺酰基嘧啶羧酸衍生物作为具有有效抗阿尔茨海默病作用的潜在多靶标药物:设计、合成、晶体结构和体外生物学评价。
Eur J Med Chem. 2021 Apr 5;215:113224. doi: 10.1016/j.ejmech.2021.113224. Epub 2021 Feb 2.
5
Design, synthesis and biological activity of novel tacrine-isatin Schiff base hybrid derivatives.新型他克林-靛红席夫碱杂合衍生物的设计、合成与生物活性。
Bioorg Chem. 2019 Aug;89:103006. doi: 10.1016/j.bioorg.2019.103006. Epub 2019 May 21.
6
Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors Based on the Pyridyl-Pyridazine Moiety for the Potential Treatment of Alzheimer's Disease.基于吡啶基哒嗪部分的新型双乙酰胆碱酯酶和丁酰胆碱酯酶抑制剂用于阿尔茨海默病的潜在治疗
Pharmaceuticals (Basel). 2024 Oct 21;17(10):1407. doi: 10.3390/ph17101407.
7
Biological evaluation of synthetic α,β-unsaturated carbonyl based cyclohexanone derivatives as neuroprotective novel inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid-β aggregation.基于合成α,β-不饱和羰基的环己酮衍生物作为乙酰胆碱酯酶、丁酰胆碱酯酶和淀粉样β蛋白聚集的神经保护新型抑制剂的生物学评价
Bioorg Med Chem. 2016 May 15;24(10):2352-9. doi: 10.1016/j.bmc.2016.04.015. Epub 2016 Apr 8.
8
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.新型阿魏酸-O-烷基胺衍生物的设计、合成及评价:作为治疗阿尔茨海默病的多功能药物。
Eur J Med Chem. 2017 Apr 21;130:379-392. doi: 10.1016/j.ejmech.2017.02.039. Epub 2017 Feb 20.
9
Development of the "hidden" multi-target-directed ligands by AChE/BuChE for the treatment of Alzheimer's disease.通过 AChE/BuChE 开发用于治疗阿尔茨海默病的“隐藏”多靶标导向配体。
Eur J Med Chem. 2023 May 5;251:115253. doi: 10.1016/j.ejmech.2023.115253. Epub 2023 Mar 10.
10
Aaptamine - a dual acetyl - and butyrylcholinesterase inhibitor as potential anti-Alzheimer's disease agent.阿朴卡林 - 一种双重乙酰胆碱酯酶和丁酰胆碱酯酶抑制剂,有望成为治疗阿尔茨海默病的药物。
Pharm Biol. 2022 Dec;60(1):1502-1510. doi: 10.1080/13880209.2022.2102657.

本文引用的文献

1
Multi Targeted Therapy for Alzheimer's Disease by Guanidinium-Modified Calixarene and Cyclodextrin Co-Assembly Loaded with Insulin.载胰岛素的胍基修饰杯芳烃与环糊精共组装体对阿尔茨海默病的多靶点治疗
ACS Nano. 2024 Dec 3;18(48):33032-33041. doi: 10.1021/acsnano.4c05693. Epub 2024 Nov 5.
2
Pharmacological Activities and Molecular Mechanisms of Sinapic Acid in Neurological Disorders.芥子酸在神经紊乱中的药理作用和分子机制。
ACS Chem Neurosci. 2024 Aug 21;15(16):2966-2981. doi: 10.1021/acschemneuro.4c00349. Epub 2024 Jul 31.
3
Electrocatalytic C-H/S-H Coupling of Amino Pyrazoles and Thiophenols: Synthesis of Amino Pyrazole Thioether Derivatives.氨基吡唑与苯硫酚的电催化C-H/S-H偶联:氨基吡唑硫醚衍生物的合成
J Org Chem. 2024 Apr 19;89(8):5434-5441. doi: 10.1021/acs.joc.3c02888. Epub 2024 Apr 6.
4
Quercetin: A promising therapy for diabetic encephalopathy through inhibition of hippocampal ferroptosis.槲皮素:通过抑制海马体铁死亡治疗糖尿病性脑病的一种有前景的疗法。
Phytomedicine. 2024 Apr;126:154887. doi: 10.1016/j.phymed.2023.154887. Epub 2023 May 20.
5
Development of substituted benzylidene derivatives as novel dual cholinesterase inhibitors for Alzheimer's treatment.开发取代亚苄基衍生物作为治疗阿尔茨海默病的新型双胆碱酯酶抑制剂。
RSC Adv. 2023 Sep 4;13(38):26344-26356. doi: 10.1039/d3ra03224h.
6
Novel Probucol Analogue, 4,4'-Diselanediylbis (2,6-Di--Butylphenol), Prevents Oxidative Glutamate Neurotoxicity and Confers Neuroprotection in a Rodent Model of Ischemic Stroke.新型普罗布考类似物,4,4'-二硒代亚乙基双(2,6-二叔丁基苯酚),可预防氧化谷氨酸神经毒性,并在缺血性中风啮齿动物模型中提供神经保护作用。
ACS Chem Neurosci. 2023 Aug 16;14(16):2857-2867. doi: 10.1021/acschemneuro.3c00138. Epub 2023 Jul 27.
7
Butyrylcholinesterase in lipid metabolism: A new outlook.酰基胆碱酯酶在脂代谢中的作用:新视角。
J Neurochem. 2024 Apr;168(4):381-385. doi: 10.1111/jnc.15833. Epub 2023 May 11.
8
Development of thiazole-appended novel hydrazones as a new class of α-amylase inhibitors with anticancer assets: an and approach.噻唑附加新型腙类化合物作为一类具有抗癌特性的新型α-淀粉酶抑制剂的开发:一种综合方法。
RSC Med Chem. 2023 Feb 6;14(4):757-781. doi: 10.1039/d2md00431c. eCollection 2023 Apr 26.
9
Design, synthesis and biological evaluation of novel histone deacetylase (HDAC) inhibitors derived from -elemene scaffold.新型组蛋白去乙酰化酶(HDAC)抑制剂的设计、合成与生物评价,源于榄香烯骨架。
J Enzyme Inhib Med Chem. 2023 Dec;38(1):2195991. doi: 10.1080/14756366.2023.2195991.
10
Mitochondrial dysfunctions, oxidative stress and neuroinflammation as therapeutic targets for neurodegenerative diseases: An update on current advances and impediments.线粒体功能障碍、氧化应激和神经炎症作为神经退行性疾病的治疗靶点:当前进展与障碍的最新情况
Neurosci Biobehav Rev. 2023 Jan;144:104961. doi: 10.1016/j.neubiorev.2022.104961. Epub 2022 Nov 14.